SGLT2 Inhibitors Reduce Heart Failure Hospitalization, Cardiovascular Death and Kidney Outcomes in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
In brief
SGLT2 inhibitors cut heart failure hospitalization or cardiovascular death by 23%
In a meta-analysis of 14 trials involving nearly 77,000 adults with type 2 diabetes, sodium-glucose cotransporter-2 inhibitors reduced the combined risk of heart failure hospitalization or cardiovascular death by 23%; heart failure hospitalization alone fell 29%, and composite kidney outcomes fell 31%. Kidney findings varied across trials, and differing definitions limit comparisons, but the overall results support cardiorenal benefits across risk groups.
- Journal
- Diabetes, obesity & metabolism (Q1)
- Published
- 13 October 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Ahmed Elbataa, Ahmed Mansour, Ahmed Elazab, Ammer Alabed, Rotana Jawed Masood, Afaf Fayez Albogami, et al.
- PMID
- 42865310
- DOI
- 10.1111/dom.71411
Why clinicians should know about it
- Picked for Internal Medicine (paper of the day, 14 October 2026): Meta-analysis of RCTs, SGLT2i reduce HF hospitalisation
- Picked for Family Practice (paper of the day, 14 October 2026): Meta‑analysis of SGLT2 inhibitors on HF and renal outcomes in
Abstract
BACKGROUND: Cardiovascular disease and chronic kidney disease are the principal drivers of morbidity and mortality in type 2 diabetes mellitus (T2DM). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated cardiorenal benefits in landmark trials, yet cross-trial inconsistencies in cardiovascular mortality, renal endpoints and drug-specific effects leave the class-level estimates incompletely synthesized. METHODS: PubMed, Web of Science, Scopus and CENTRAL were searched from inception through 15 May 2026. Large placebo-controlled RCTs (≥ 1000 participants) and prespecified subgroup analyses in adults with T2DM were eligible. The primary outcome was the composite of first hospitalization for heart failure (HHF) or cardiovascular death (CV death). Secondary outcomes were 3-point major adverse cardiovascular events (MACE), CV DEATH, myocardial infarction (MI), stroke, first HHF and composite kidney outcomes. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using random-effects inverse-variance models. RESULTS: Fourteen studies (76 969 patients; 41 761 SGLT2i, 35 208 placebo) were included. SGLT2i reduced the primary composite by 23% (HR: 0.77, 95% CI: 0.73-0.81, p < 0.0001; I2 = 0%), with no effect modification by baseline HF (p-interaction = 0.82) or established ASCVD (p-interaction = 0.46). MACE was reduced by 14% (HR: 0.86, 95% CI: 0.81-0.92), driven by significant reductions in CV DEATH (HR: 0.86, 95% CI: 0.79-0.93) and MI (HR: 0.88, 95% CI: 0.81-0.96), with no significant effect on stroke (HR: 0.93, 95% CI: 0.81-1.08). First, HHF was reduced by 29% (HR: 0.71, 95% CI: 0.66-0.77) and composite kidney outcomes by 31% (HR: 0.69, 95% CI: 0.60-0.79). CONCLUSIONS: SGLT2i confer consistent and clinically meaningful cardiorenal protection in T2DM across the full spectrum of cardiovascular and renal risk. The ertugliflozin estimate and the moderate heterogeneity in kidney outcomes should be interpreted in the context of trial-level clinical differences and nonstandardized kidney endpoint definitions. These findings support proactive, guideline-concordant initiation of evidence-based SGLT2i agents by endocrinologists, cardiologists and primary care providers as foundational therapy in T2DM.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.